World's Best Scientists 2026 revealed!
Tetsuji Naka

Tetsuji Naka

D-Index & Metrics

Immunology

D-Index
70
Citations
22030
World Ranking
2386
National Ranking
90

Tetsuji Naka publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Tetsuji Naka sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 314 publications — 67th percentile

67% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Tetsuji Naka D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Tetsuji Naka sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 70 D-Index — 52nd percentile

52% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Tetsuji Naka is affiliated with Kōchi University in Japan. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a significant focus on Oncology, Cancer Research, and Molecular Biology as prominent subfields. Additional subfields include Pulmonary and Respiratory Medicine and Immunology.

The main topics of Tetsuji Naka's work encompass:

  • Cancer, Lipids, and Metabolism
  • Clusterin in disease pathology
  • Cancer, Hypoxia, and Metabolism
  • Angiogenesis and VEGF in Cancer
  • Glycosylation and Glycoproteins Research
  • Ferroptosis and cancer prognosis
  • Cytokine Signaling Pathways and Interactions

Frequent publication venues for Naka include:

  • Cancer Research
  • Gastric Cancer
  • Annals of the Rheumatic Diseases
  • E-Posters
  • Anticancer Research

Notable recent papers authored or co-authored by Naka feature a range of topics in disease biomarkers, cancer therapies, and mechanisms of cancer cell regulation:

  • Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study, 2021, Journal of Gastroenterology
  • GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab, 2020, eLife
  • SOCS1 Gene Therapy for Head and Neck Cancers: An Experimental Study, 2022, Anticancer Research
  • Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer, 2020, British Journal of Cancer
  • Propranolol suppresses gastric cancer cell growth by regulating proliferation and apoptosis, 2021, Gastric Cancer

Among frequent co-authors are researchers such as Satoshi Serada, Minoru Fujimoto, Kosuke Hiramatsu, Yutaka Ueda, and Tadashi Kimura, indicating collaboration across multiple projects with varying focus areas within oncology and biomedical research.

Best Publications

  • SOCS proteins, cytokine signalling and immune regulation.

    Akihiko Yoshimura;Tetsuji Naka;Masato Kubo

  • Structure and function of a new STAT-induced STAT inhibitor

    Tetsuji Naka;Masashi Narazaki;Moritoshi Hirata;Tomoshige Matsumoto

  • The immune responses in CD40-deficient mice: Impaired immunoglobulin class switching and germinal center formation

    Tsutomu Kawabe;Tetsuji Naka;Kanji Yoshida;Takashi Tanaka

  • SOCS-1 participates in negative regulation of LPS responses.

    Reiko Nakagawa;Tetsuji Naka;Hiroko Tsutsui;Minoru Fujimoto

  • The paradigm of IL-6: from basic science to medicine

    Tetsuji Naka;Norihiro Nishimoto;Tadamitsu Kishimoto

  • Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells

    Akihiro Kimura;Tetsuji Naka;Keiko Nohara;Yoshiaki Fujii-Kuriyama

  • Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses

    Akihiro Kimura;Tetsuji Naka;Taisuke Nakahama;Ichino Chinen

  • IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells

    Akihiro Kimura;Tetsuji Naka;Tadamitsu Kishimoto

  • IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis.

    Satoshi Serada;Minoru Fujimoto;Masahiko Mihara;Nobuo Koike

  • Therapeutic strategies in epithelial ovarian cancer

    Ayako Kim;Yutaka Ueda;Tetsuji Naka;Takayuki Enomoto

  • Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice

    Tetsuji Naka;Tomoshige Matsumoto;Masashi Narazaki;Minoru Fujimoto

  • THREE DISTINCT DOMAINS OF SSI-1/SOCS-1/JAB PROTEIN ARE REQUIRED FOR ITS SUPPRESSION OF INTERLEUKIN 6 SIGNALING

    Masashi Narazaki;Minoru Fujimoto;Tomoshige Matsumoto;Yoshiaki Morita

  • Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.

    Minoru Fujimoto;Satoshi Serada;Masahiko Mihara;Yasushi Uchiyama

  • Regulation of cytokine signaling by SOCS family molecules

    Minoru Fujimoto;Tetsuji Naka

  • Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation

    Yoh Ichi Seki;Katsuhiko Hayashi;Akira Matsumoto;Akira Matsumoto;Noriyasu Seki

  • Signals transducers and activators of transcription (STAT)-induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor necrosis factor α-induced cell death in fibroblasts

    Yoshiaki Morita;Tetsuji Naka;Yoshinori Kawazoe;Minoru Fujimoto

  • Suppressor of cytokine signaling-1 selectively inhibits LPS-induced IL-6 production by regulating JAK-STAT.

    Akihiro Kimura;Tetsuji Naka;Tatsushi Muta;Osamu Takeuchi

  • Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis

    Satoshi Serada;Minoru Fujimoto;Fumitaka Terabe;Hideki Iijima

  • The absence of IgE antibody-mediated augmentation of immune responses in CD23-deficient mice.

    H Fujiwara;H Kikutani;S Suematsu;T Naka

  • iTRAQ-based proteomic identification of leucine-rich alpha-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases.

    Satoshi Serada;Minoru Fujimoto;Atsushi Ogata;Fumitaka Terabe

  • Signal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 (SOCS1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate 1 (IRS-1) phosphorylation.

    Yoshinori Kawazoe;Tetsuji Naka;Minoru Fujimoto;Hidetsugu Kohzaki

  • CLONING AND FUNCTIONAL ANALYSIS OF NEW MEMBERS OF STAT INDUCED STAT INHIBITOR (SSI) FAMILY : SSI-2 AND SSI-3

    Seijiro Minamoto;Kazuhiro Ikegame;Kiyonobu Ueno;Masashi Narazaki

Frequent Co-Authors

Minoru Fujimoto
Minoru Fujimoto Kōchi University
Tadamitsu Kishimoto
Tadamitsu Kishimoto Osaka University
Tadashi Kimura
Tadashi Kimura Osaka University
Yuichiro Doki
Yuichiro Doki Osaka University
Masaki Mori
Masaki Mori Kyushu University
Manabu Fujimoto
Manabu Fujimoto Osaka University
Eiichi Morii
Eiichi Morii Osaka University
Kenji Nakanishi
Kenji Nakanishi Hyogo College of Medicine
Hiroko Tsutsui
Hiroko Tsutsui Hyogo College of Medicine
Shintaro Nomura
Shintaro Nomura Nomura Holdings (Japan)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Immunology opens doors to various healthcare careers, many of which can be pursued through flexible online programs. For those interested in nursing but starting without a clinical background, online RN programs for non nurses offer an excellent pathway to gain essential nursing credentials efficiently.

Accelerated nursing programs are another attractive option, especially for individuals eager to transition into nursing quickly. Programs like absn programs with high acceptance rates tend to have more accessible admission criteria, making them great choices for new students aiming for a Bachelor of Science in Nursing.

For those seeking quicker entry into nursing roles, lpn programs with easiest admission requirements provide opportunities to become Licensed Practical Nurses with less demanding prerequisites. These programs serve as a foundational step toward advanced immunology-related careers in clinical settings.

Finally, for nursing professionals looking to specialize further, there are easiest NP programs to get into that offer streamlined paths to become Nurse Practitioners. Such advanced degrees complement immunology expertise, enhancing career prospects in healthcare and research.

Best Scientists Citing Tetsuji Naka

Trending Scientists

Recently Published Articles